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Background: Behcet’s disease is an autoimmune, recurrent and multisystem disease. Vitamin D has
immunomodulator role in immune system. So that vitamin D deficiency was reported in some autoimmune
diseases. Behcet’s disease as a Silk Road disease is common in Iran. The aim of this study was to detect the serum
level of 25(OH) vitamin D in Behcet’s patients and control group.
Methods: In this case–control study, 112 Behcet’s patients as cases group and 112 healthy individuals as controls
group were enrolled. Any subject on vitamin D supplement, steroid, and immunosuppressors during the last 6
months were excluded. The serum level of 25(OH) vitamin D was measured in the two groups by ELISA method.
The findings were compared via SPSS software.
Results: About 57% and 17% of Behcet’s patients had vitamin D deficiency and insufficiency respectively. Vitamin D
deficiency was significantly more common in controls than cases group (P < 0.001). Vitamin D levels were
significantly lower in controls (P < 0.001). Age and sex did not have any confounding effect on the results. There
was no significant relationship between disease duration, disease activity, Pathergy test, HLA-B5, and HLA-B51 with
vitamin D level in Behcet’s patients.
Conclusions: Vitamin D deficiency is common among Behcet’s patients. However, our results revealed vitamin D
deficiency was significantly more common in healthy controls in comparison with Behcet’s cases.
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Behcet’s disease (BD) is a chronic relapsing disease of
autoimmune nature which involves multiple systems
[1,2]. One of the characteristics of this disease is its mu-
cocutaneous lesions (oral or genital aphthosis), major
organ involvements such as ocular, CNS or vascular
manifestations [3,4]. The disease is known for its ethnic
basis, spreading through ancient Silk Road [5,6]. Iran is
the second most prominent foci for BD with preva-
lence rate of 80 out of 100,000 [7]. The ethiopathogenesis
of Behcet’s disease is not fully understood. However, gen-
etical, environmental and immunological factors contrib-
ute to disease progression [8-10]. Immune mechanisms
play a major role in Behcet’s disease [11]. Heat shock pro-
teins, cytokines, alterations in neutrophil and macrophage* Correspondence: s.t_faezi@yahoo.com
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reproduction in any medium, provided the oractivity, and autoimmune mechanisms have all been
implicated [12-15]. Circulating immune complexes also
play a role in precipitating the characteristic neutrophilic
vascular reaction [16].
Active vitamin D (Vit-D), or 1,25(OH) D3 has been
linked with the metabolism of calcium and phosphorus
[11]. Moreover, studies have unraveled the role of vita-
min D in the regulation of immune responses [12]. Known
roles of vitamin D in immune system include inhibiting
proliferation of T Helper1 cells [13,14], stimulation of
regulatory T-cells [15,16], diminishing B-lymphocyte dif-
ferentiation and inhibiting immunoglobulin secretion [17].
In addition, restricted antigen presentation via macro-
phages and modulation of dendritic cells maturation have
been linked with vitamin D [18]. Previous studies have di-
vulged lower levels of 25(OH) Vitamin D in autoimmune
diseases such as Diabetes Mellitus, Systemic lupus ery-
thematosus (SLE), Multiple sclerosis, inflammatory boweld. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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healthy individuals [19-22]. Due to high prevalence of
Behcet’s disease in Iran and the important role of vitamin
D in the autoimmune responses, we conducted this study
to evaluate vitamin D level in BD patients and investigate
whether a difference in vitamin D level exist between BD
cases and healthy controls.
Patients and methods
The applied protocol in the current research project
has been approved by Ethical Board Committee of the
Rheumatology research center. Patients group comprised
of cases who were referred to Behcet’s clinic and diag-
nosed with Behcet’s disease according to international
study group criteria (ISG) for BD. Exclusion criteria for
BD subgroup consisted of history of taking any kind of
vitamin D supplements (pearl, injection, Multivitamin
or Ca-D), any kind of corticosteroids or cytotoxic drugs
during the last 6 months. Control group, included healthy
volunteers from the staff of Shariati hospital. Individuals
with history of chronic disease including renal or hepatic
diseases, bone metabolic disease, malabsorption, type 1
diabetes mellitus or malignancies were excluded from
study. Furthermore controls with history of vitamin D,
Ca-D, Multivitamin or any drug affecting bone metabol-
ism (such as phenobarbital or phenytoin) in the last 6
months were excluded. Patients and controls were as-
cribed consecutively after explanation of study plot. Pa-
tients who agreed on the terms of the study were asked
to sign a written informed consent form. Thereafter pa-
tients were introduced to the lab of the Endocrinology
and Metabolism Research Institute (EMRI) of Tehran
University of Medical Sciences. Vitamin D measure-
ments were performed via ELISA method. Vitamin D
levels lower than 20 ng/ml were ascribed to “vitamin D
deficiency” category. Vitamin D levels higher than 20 ng/ml
and lower than 32 ng/ml were ascribed to “vitamin D
insufficiency” and higher than 32 ng/ml of vitamin D
were categorized as “Normal”. Patients’ characteristics
including demographic features, disease duration, and
clinical manifestations were registered through patients’
files and Behcet’s clinic registry. Furthermore, we uti-
lized a tailored questionnaire for each patient to detail
patients’ therapeutic and follow up information. The
Rheumatologists of Behcet’s clinic exclusively assessed
disease activity in each patient. According to the PhysicianTable 1 Serum vitamin D level in Behcet’s cases and controls
Vitamin D level Sex Deficiency number (%) Insuf
BD patients Male 23(20.5%) 9(8.0
Female 41(36.6%) 10(8.
Controls Male 22(19.6%) 0
Female 80(71.4%) 3(2.7Global Assessment (PGA) BD was divided to active and
silent statuses. Active status was subdivided into three
subgroups of “mild”, “moderate” and “severe”. SPSS 20.0
software was utilized to analyze the extracted data and
comparison between various subgroups.
Results
A total number of 224 BD patients and healthy controls
were studied. BD subgroup comprised of 112 cases (46
males and 66 females) with mean age of 40.5 years
(range: 18–70). Controls comprised of 112 healthy indi-
viduals (22 males and females) with mean age of 37.5
years (range: 23–65). Among BD patients 57.1% had
vitamin D deficiency and 16.9% had vitamin D insuffi-
ciency. Meanwhile in control group, 91.1% had Vit-D
deficiency and 2.7% had vitamin D insufficiency. These
findings indicate a significant difference between BD pa-
tients and controls in prevalence of vitamin D deficiency
(P < 0.001). Average level of vitamin D in BD cases and
healthy controls were 24.4 ± 2.5 and 11.1 ± 1.6 ng/ml re-
spectively (P < 0.001) (Table 1).
Female individuals constitute 58.9% of BD cases and
80.4% of controls. Therefore a significant difference in
gender distribution between BD and control subgroup
existed (P < 0.001). In BD patients a significant difference
between men and women was detected in vitamin D level
(24.8 ± 3.9 ng/ml in women vs. 23.7 ± 2.4 ng/ml in men,
P = 0.039). On the contrary, comparison of vitamin D levels
between male and female individuals of the control group
did not reveal a significant difference (12.1 ± 1.9 ng/ml
in female controls vs. 6.9 ± 0.9 ng/ml in male controls,
P = 0.064). Mean age of BD patients and controls were
40.5 ± 1.03 and 37.5 ± 0.7 respectively (P = 0.010). Our
analysis revealed no significant correlation between age
and vitamin D level (P = 0.055, r = 0.128).
Turkish ethnicity was significantly more common in
BD cases in comparison with controls (43.8% vs. 24.1%,
P = 0.002). In BD patients no significant difference in
vitamin D level was detected between Turkish and Non-
Turkish cases (31.02 ± 4.9 in Turkish and 19.2 ± 2.1 ng/ml
in Non-Turkish patients, P = 0.055). Likewise, no sig-
nificant difference in vitamin D levels in Turkish and
Non-Turkish controls was detected (8.3 ± 1.1 vs. 11.9 ±
2.09 ng/ml, P = 0.114).
In BD group the mean time span from BD criteria ful-
fillment and established diagnosis to last patients’ visit togroup
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between diagnosis to last visit interval and vitamin D
level was detected (P = 0.071, r = 0.171). Mean time
interval between onset sign and last patient’s visit to BD
clinic was 14.5 ± 8.8 years. No correlation between disease
duration (time span from onset sign to last visit) and
vitamin D level was detected (P = 0.071, r = 0.171).
Twenty-one BD patients (18.7%) had active disease
while 91 (81.3%) were in remission. No correlation be-
tween disease activity and vitamin D levels was present
(P = 0.145, r = 0.138). In 14 cases (12.5%) mild disease
activity and in 7 cases (6.2%) moderate disease activity
was noted. None of the studied cases had severe BD activ-
ity. Among BD patients, positive pathergy test was ob-
tained in 69 cases. In this subpopulation mean vitamin D
levels was 24.7 ± 3.4 ng/ml. On the other hand, in 31 BD
patients who had negative pathergy test, mean vitamin D
level was 25.5 ± 4.8 ng/ml. Vitamin D measurements did
not reveal significant difference between these two sub-
groups (P = 0.772).
In BD patients, HLA-B51 was positive in 36 cases
(40.9%) with mean vitamin D level of 19.8 ± 3.4 ng/ml
and negative in 52 cases (59.1%) with mean vitamin D
level of 24.2 ± 3.4 ng/ml. Statistical analysis revealed no
significant difference between these two subgroups of
BD (P = 0.248). Positive HLA-B5 was detected in 53 BD
cases (53.5%), while 46 BD cases had negative HLA-B5
(46.5%). Mean vitamin D level in HLA-B5 positive pa-
tients was 25.1 ± 3.6 and in HLA-B5 negative cases it
was 21.88 ± 3.4 ng/ml (P = 0.776).Discussion
Vitamin D deficiency is a global public health concern
which affects various age groups [23]. Arabi et al. reported
hypovitaminosis D is encountered in 33 to 50% of general
population in Sub-Saharan Africa and Middle East [24].
Previous surveys in Middle East have pointed out the
sun exposure, latitude, Islamic clothing, body mass index
(BMI), Calcium supplements and genetic factors are major
determinants of vitamin D level [25-28].
One of the essential attributes of vitamin D is the immu-
noregulatory role [29-31]. Therefore vitamin D deficien-
cies need to be comprehensively addressed in patients
with immunologic aberrancies. The optimum serum level
of vitamin D which facilitates efficient immune responses
is not precisely determined. However it is believed to be
lower than vitamin D required level in healthy bone me-
tabolism [12]. Plethora of studies has unraveled the higher
rate of vitamin D deficiency among patients with auto-
immune diseases, adding that the condition is correlated
with disease activity [12,30,32,33]. It has been postulated
that vitamin D deficiency results in diminished regulator
T- cells and shifts Th1/Th2 ratio toward Th1 [34]. Thesefindings underline the modulatory effect of vitamin D on
T cells and inflammatory mediators [34].
Previous studies have investigated the vitamin D status
in Behcet’s disease [29,34,35]. A number of these studies
have revealed lower levels of serum vitamin D in active
BD in comparison with normal controls [29,35,36].
Kandi et al. detected lower levels of vitamin D in BD pa-
tients in comparison with controls group. However this
difference was not significant [37]. On the contrary our
study unraveled a significantly higher level of vitamin D
in BD patients in comparison with controls. The contro-
versy may be partly due to the inclusion criteria of
current study which excluded BD cases with severe ac-
tivity. Moreover patients and controls were gathered at
different timeframes which might have affected the re-
sults. Blood samples of BD patients were collected in
late summer and early autumn, while as for the controls,
they were recruited in late autumn and early winter.
BD patients are exclusively consulted on issues such as
life style, physical activity and nutrition and have a better
insight about their general health status. We postulated
that the tailored education of BD patients may attribute
to the lower rate of vitamin D deficiency. On the other
hand, the considerable prevalence of vitamin D deficiency
and insufficiency in our control group may indicate
the poor health education in general population as
well as other parameters such as lack of sun exposure
or nutrition.
A number of studies have unraveled the positive relation
between BD activity and vitamin D deficiency [29,35,36].
Another study by Hamzaoui et al. revealed lower level of
vitamin D in active BD cases in comparison with silent BD
cases and control group. However these results did not re-
veal a significant correlation between disease activity and
vitamin D level [34]. Likewise we did not detect a signifi-
cant correlation between disease activity or severity and
vitamin D level. It is noteworthy that BD cases with severe
activity were excluded in accordance with the instructions
of our study. This is due to timely administration of
immunosupressors and corticosteroids in patients with se-
vere BD which met exclusion criteria of our study. There-
fore Behcet’s disease was silent in most of studied patients
(80%) at the time of study. The remaining 20% of BD
patients were mostly comprised of mildly-active patients.
Our results revealed high rate of Vitamin D deficiency
in control group and the overall figures demonstrated
very low levels of serum vitamin D in majority of studied
control population. These findings are in accordance with
previous studies in Tehran and Iran, which had revealed
the magnitude of problem in Iran [25,26]. According to
the nationwide survey 75% of Iranian women and 72% of
Iranian men suffer from vitamin D deficiency [25]. The
higher rate of hypovitaminosis D in control group of our
study (91% had vitamin D deficiency, and 2.7% had
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exposure in the season of controls group enrollment (au-
tumn and winter) and the younger age. Hashemipour
et al. reported mean serum vitamin D level significantly
increased with age in Iranian women [26]. In the current
study, mean age of controls group was significantly
lower than BD patients. Moreover mean age of both BD
and control groups were lower than previous nationwide
surveys. Thus the age parameter may partially justify the
higher prevalence of hypovitaminosis D in our control
group in comparison with nationwide survey.
Another factor which must be addressed is the Islamic
clothing in Iranian women which may be influential as
the significant difference in gender distribution existed
between control and BD groups. However when patients
and controls of both genders were compared separately,
higher rate of vitamin D deficiency in two genders was
redetected in both control and BD groups.
Ethnic distribution varied between control and BD
groups as Turk patients are the majority of BD population,
whilst controls resembled the overall distribution of eth-
nicities in Iran. However, our data analysis detected no sig-
nificant difference in vitamin D level between Turkish and
non-Turkish participants in both control and BD groups.
In the current study 37% of BD patients had a history
of corticosteroid administration. The analysis revealed no
significant difference in vitamin D level between patients
who had received corticosteroid and patients who had
not. This may be due to discontinuation of corticosteroid
during 6 month period prior to enrollment which was a
part of inclusion criteria.
In comparison with studies on other rheumatologic
conditions, vitamin D deficiency was more prevalent
among our BD group in comparison with Iranian SLE
and RA cases [38,39]. These findings stress the necessity
of vitamin D control in BD patients.
In majority of BD cases (69%), pathergy test was posi-
tive; however, no significant difference between pathergy
reaction positivity and vitamin D level was noted. Likewise
no correlation between HLA-B5 and HLA-B51 immuno-
reaction and vitamin D level was detected. These findings
may downplay role of genetic factors in hypovitaminosis
D in BD cohort.
To our knowledge previous studies had not assessed the
correlation between factors such as HLA-B5, HLA-B51,
pathergy test and mean disease duration and vitamin D
level in BD.
This study had a number of limitations. We could not
evaluate the confounding impact of some factors such as
nutrition, BMI or genetic predisposition. Our BD cases
were referred to the Behect’s clinic from various regions
of our country, while all controls were inhabitants in
Tehran, the Iranian capital. We could not synchronically
enroll patients and controls in a same season therefore aseasonal difference existed between two groups. More
scrutinized studies in Iranian BD patients are warranted
to investigate the link between specific features of BD
and serum vitamin D level.
Conclusion
Our study stressed the high prevalence of vitamin D de-
ficiency in BD population. However, in comparison with
normal population; BD patients had significantly higher
level of serum vitamin D which may be partly due to
insightful education they obtain in Behcet’s clinc. More-
over this study did not detect any significant correlation
between BD activity, HLA-B5, HLA-B51 and vitamin D
level. However, more scrutinized studies are warranted
to address the issue of vitamin D deficiency in BD and
its relation with disease activity.
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